NK cells and DCs are currently used for immunotherapies to treat tumor patients, for NK cells exhibit the ability to directly eliminate tumor cells without prior sensitization, while DCs are able to initiate an immune response by presenting antigens and inducing tumor-antigen specific CD8+ T cell (2). Here, CD8A is linked to neoplasm.